ストックスクリーナーアプリを入手
1.56
7.45%
-0.1255
前日終値:
$1.6855
開ける：
$1.65
24時間の取引高:
740
Relative Volume:
0.08
時価総額：
$136.44M
収益：
$47.04M
当期純損益:
$-63.98M
株価収益率:
-1.9345
EPS:
-0.8064
ネットキャッシュフロー:
$-34.39M
1週間 パフォーマンス:
-6.31%
1か月 パフォーマンス:
-18.75%
6か月 パフォーマンス:
-46.21%
1年 パフォーマンス:
-35.80%
1日の値動き範囲:
$1.56
$1.65
1週間の範囲:
$1.29
$1.70
52週間の値動き範囲:
$1.29
$3.15
Innate Pharma Adr Stock (IPHA) Company Profile
IPHA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| IPHA | 1.56 | 136.44M | 47.04M | -63.98M | -34.39M | -0.8064 |
| VRTX | 449.74 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.06 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.30 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.17 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-09-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | 開始されました | Goldman | Neutral |
Innate Pharma Adr (IPHA) 最新ニュース
Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies By Investing.com - Investing.com UK
Earnings call: Innate Pharma reports progress in drug development - Investing.com India
Earnings call: Innate Pharma reports progress in oncology pipeline - Investing.com
Innate Pharma S.A. ADR (IPHA-Q) QuotePress Release - The Globe and Mail
Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update - The Globe and Mail
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update - The Globe and Mail
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag - Yahoo Movies UK
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting - Investing.com India
Earnings call: Innate Pharma reveals Q1 2024 results and pipeline progress - Investing.com
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis - Zacks Investment Research
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities News
The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine ... - Yahoo Finance
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/ - Benzinga
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Sh - Benzinga
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
Innate Pharma Adr (IPHA) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):